Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, Hales RK, Voong KR, Battafarano RJ, Jobe BA, Yang SC, Broderick S, Ha J, Marrone KA, Pereira G, Rao N, Borole A, Karaindrou K, Belcaid Z, White JR, Ke S, Amjad AI, Weksler B, Shin EJ, Thompson E, Smith KN, Pardoll DM, Hu C, Feliciano JL, Anagnostou V, Lam VK.
Kelly RJ, et al. Among authors: anagnostou v.
Nat Med. 2024 Apr;30(4):1023-1034. doi: 10.1038/s41591-024-02877-z. Epub 2024 Mar 19.
Nat Med. 2024.
PMID: 38504015
Free PMC article.
Clinical Trial.